Novonesis (Novozymes) B (OTCPK:NVZMF)
$ 60.875 1.133 (1.9%) Market Cap: 28.48 Bil Enterprise Value: 30.18 Bil PE Ratio: 38.65 PB Ratio: 2.42 GF Score: 97/100

Q1 2020 Novozymes A/S Earnings Call Transcript

Apr 29, 2020 / 07:00AM GMT
Release Date Price: $48.9 (+4.40%)
Tobias Cornelius Bjorklund;S;Head of IR;Ester Baiget;S<
Novozymes A;Novozymes A

/-

Good morning, everyone, and welcome to this Novozymes conference call. Thank you all for calling in. My name is Tobias Bjorklund, and I'm the Head of Investor Relations. I'm joined here today by the full management team as well as the rest of the Investor Relations team. Our CEO, Ester Baiget, will begin today's call by reviewing our performance in the first quarter, followed by CFO, Lars Green, who will take -- who will cover the financials. The presentation should take around 15 minutes. And after that, we will be happy to take your questions.

Some of the matters we will discuss in this conference call are forward-looking. And I would like to remind you that these forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

With that, I will now hand you over to our CEO, Ester Baiget. Ester, please?

- /

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot